Hypertension

•	Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers Kalaitzidis R, Bakris G Diabetes, Obesity and Metabolism. 2009;11(8):757-769
•	Blood pressure variables and cardiovascular risk: new findings from ADVANCE Kengne AP, Czernichow S, Huxley R, et al, for the ADVANCE Collaborative Group Hypertension. 2009;54(2):399-404
•	Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years Kahn HS, Cheng YJ, Thompson TJ, Imperatore G, Gregg EW Ann Intern Med. 2009;150(11):741-751
•	Serum amyloid A, C-reactive protein, and retinal microvascular changes in hypertensive diabetic and nondiabetic individuals: an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy. Stettler C, Witt N, Tapp RJ, et al Diabetes Care. 2009;32(6):1098-1100
•	Uncontrolled diabetes increases the risk of Alzheimer's disease: a population-based cohort study Xu WL, von Strauss E, Qiu CX, Winblad B, Fratiglioni L Diabetologia. 2009 Mar 12. [Epub ahead of print]
•	The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient Fruchart JC, Sacks FM, Hermans MP, et al, for the Residual Risk Reduction Initiative (R3I) Diab Vasc Dis Res. 2008;5(4):319-35
•	An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients Koro CE, Fu Q, Stender M Pharmacoepidemiol Drug Saf. 2008;17(10):989-986
•	Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis Horvath K, Jeitler K, Siering U, et al Arch Intern Med. 2008;168(6):571-580
•	Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial Howard BV, Roman MJ, Devereux RB, Fleg JL, Galloway JM, Henderson JA, Howard WJ, Lee ET, Mete M, Poolaw B, Ratner RE, Russell M, Silverman A, Stylianou M, Umans JG, Wang W, Weir MR, Weissman NJ, Wilson C, Yeh F, Zhu J JAMA. (14):1678-89
•	Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Riche DM, Valderrama R, Henyan NN Diabetes Care. 2007 Feb ; 30(2): 384-388
•	Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, for the BENEDICT Study Group J Am Soc Nephrol. 2006;17:3472-3481
•	Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension Park H, Hasegawa G, Obayashi H, et al Clin Chimica Acta.. 2006;374:129-134
•	Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey Resnick HE, Foster GL, Bardsley J, Ratner RE Diabetes Care. 2006;29:531-537
•	Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria Bakris GL, Ruilope LM, McMorn SO, et al J Hypertens. 2006;24:2047-2055
•	Effects of blood pressure lowering and metabolic control on systolic left ventricular function in Type II diabetes mellitus Andersen NH, Poulsen SH, Poulsen PL, et al Clin Sci (Lond). 2006;111:53-59
•	Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study Ibsen H, Olsen MH, Wachtell K, et al Diabetes Care. 2006;29:595-600
•	Management strategies for patients with hypertension and diabetes: why combination therapy is critical Giunti S, Cooper M J Clin Hypertens (Greenwich). 2006;8:108-113
•	Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension Schillaci G, Pirro M, Vaudo G, et al Hypertension. 2005;45:1078-1082
•	Influence of metabolic syndrome on hypertension-related target organ damage Mule G, Nardi E, Cottone S, et al J Intern Med. 2005;257:503-513
•	Addressing the Global Cardiovascular Risk of Hypertension Dyslipidemia Diabetes Mellitus and the Metabolic Syndrome... Bestermann W, Houston MC, Basile J, et al Am J Med Sci. 2005;329:292-305
•	Should albuminuria be a therapeutic target in patients with hypertension and diabetes? de Zeeuw D Am J Hypertension.. 2004;17:11S-15S
•	Clinical importance of microalbuminuria in diabetes and hypertension Bakris GL Curr Hypertens Rep. 2004;6:352-356
•	Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults Malik S, Wong ND, Franklin SS Circulation. 2004;110:1239-1244
•	Development of diabetes is retarded by ACE inhibition in hypertensive patients--a subanalysis of the Captopril Prevention Project (CAPPP) Niklason A, Hedner T, Niskanen L, Lanke J J Hypertens. 2004;22:645-652
•	The Importance of Blood Pressure Control in the Patient With Diabetes Bakris GL Am J Med. 2004;116(Suppl 5A):30S-38S
•	Physician, Organizational, and Patient Factors Associated With Suboptimal Blood Pressure Management in Type 2 Diabetic Patients in Primary Care Schaars CF, Denig P, Kasje WN, Stewart RE, Wolffenbuttel BHR, Haaijer-Ruskamp FM Diabetes Care. 2004;27:123-128
•	Effects of Blood Pressure Level on Progression of Diabetic Nephropathy: Results From the RENAAL Study. Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group Arch Intern Med. 2003;163:155-1565
•	Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients with Impaired Glucose Tolerance: The STOP-NIDDM Trial Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group JAMA. 2003;290:486-494
•	Pioglitazone Reduces Atherogenic Dense LDL Particles in Nondiabetic Patients With Arterial Hypertension Winkler K, Konrad T, Fullert S, Friedrich I, Destani R, et al Diabetes Care. 2003;26:2588-2594
•	Specialist Nurse-Led Intervention to Treat and Control Hypertension and Hyperlipidemia in Diabetes (SPLINT) New JP, Mason JM, Freemantle N, et al Diabetes Care. 2003;26:2250-2255
•	Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States Wolf-Maier K, Cooper RS, Banegas JR, et al JAMA. 2003;289:2363-2369
•	The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Chobanian AV, Bakris GL, Black HR, et al. JAMA. 2003;289:2560-2571
•	Effects of Pioglitazone in Nondiabetic Patients with Arterial Hypertension: A Double-Blind, Placebo-Controlled Study Füllert S, Schneider F, Haak E, et al. J Clin Endocrinol Metab. 2002 87: 5503-5506
•	Rosiglitazone Improves Insulin Sensitivity and Lowers Blood Pressure in Hypertensive Patients Raji A, Seely EW, Bekins SA, Williams GH, Simonson DC Diabetes Care. 2003. 26:172-178
•	Usefulness of Home Blood Pressure Measurement in the Morning in Type 2 Diabetic Patients Kamoi K, Miyakoshi M, Soda S, Kaneko S, Nakagawa O Diabetes Care. 2002;25:2218-2223
•	Confirmation from the Framingham Heart Study: Being Overweight Carries Increased Risk for Hypertension, Cardiovascular Disease, Hypercholesterolemia, and Diabetes
•	130/80 mm Hg: The New and Lower BP Goal for Adults With Hypertension and Diabetes
•	Unrecognized Hypertension in Diabetic Patients With Coronary

Clinical Bridges, Secaucus, NJ
Clinical Bridges is a division of KnowledgePoint360 Group, LLC.
Copyright © 2009 Clinical Bridges. All rights reserved.
National Diabetes Education Initiative, Clinical Bridges, and
KnowledgePoint360 are trademarks of KnowledgePoint360 Group, LLC.

Disclaimer Statement - Privacy Statement